Senna Versus Magnesium Oxide for the Treatment of Chronic Constipation: A Randomized, Placebo-Controlled Trial
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: This is the first prospective, double-blinded, randomized, placebo-controlled trial to evaluate the safety and efficacy of a stimulant laxative compared with an osmotic agent for the treatment of chronic idiopathic constipation. METHODS: Patients were randomly administered stimulant laxative (senna, 1.0 g), osmotic agent (magnesium oxide [MgO], 1.5 g), or placebo for 28 consecutive days. The primary endpoint was overall symptom improvement. Secondary endpoints were spontaneous bowel movement (SBM), complete SBM, and patient assessment of constipation quality of life (QOL). RESULTS: Ninety patients (mean age, 42 years; 93% women; mean duration of symptoms, 9.9 years) were enrolled; all completed the study. The response rate for overall improvement was 11.7% in the placebo group, 69.2% in the senna group, and 68.3% in the MgO group ( P < 0.0001). Change in SBM was significantly greater in the senna and MgO groups than that in the placebo group ( P < 0.001). Similarly, change in complete SBM was significantly greater in the senna and MgO groups than that in the placebo group ( P < 0.01). On the patient assessment of constipation QOL, significant improvements were seen in the senna and MgO groups compared with those in the placebo group (senna, P < 0.05; MgO, P < 0.001). The frequency of severe treatment-related adverse events was 0%. DISCUSSION: Senna and MgO significantly improved the frequency of bowel movements and QOL score and seem to be effective in the treatment of constipation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Participants treated with senna may have higher CSBMs per week (MD 7.60, 95% CI 5.90-9.30) and SBMs per week (MD 7.6, 95% CI 6.42-8.78) compared with the placebo group.”
In the citing paper
“No participants in the senna and placebo arms experienced a severe treatment-related adverse event.”
In the citing paper
“However, as Moshita et al. 44 did not provide rates for the mild treatment-related adverse events, the fact that 83% of participants with CIC randomized to senna engaged in dose reduction raises concerns about potential adverse events such as abdominal pain, cramping, or diarrhea with the higher dose of senna.”
In the citing paper
“Compared with placebo, treatment with MgO may increase the number of CSBMs per week (MD 4.29, 95% CI 2.93-5.65) and SBMs per week (MD 3.59, 95% CI 2.64-4.54).”
In the citing paper
“It is notable that while no details were provided, 83% of participants randomized to senna reduced their daily dose during the trial. 44”
Citations
Cites
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
Donovan, J. L., Hamdy, F. C., Lane, J. A., Mason, M., Metcalfe, C., Walsh, E., Blazeby, J. M., Peters, T. J., Holding, P., Bonnington, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606221 · Cited by 1,338
A constipation scoring system to simplify evaluation and management of constipated patients
Agachan, F., Chen, T., Pfeifer, J., Reissman, P., & Wexner, S. D. (1996) · Diseases of the Colon & Rectum · doi:10.1007/bf02056950 · Cited by 1,253
Mechanisms, evaluation, and management of chronic constipation
Bharucha, A. E., & Lacy, B. E. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.034 · Cited by 655
Myths and Misconceptions About Chronic Constipation
Muller-Lissner, S. A., Kamm, M. A., Scarpignato, C., & Wald, A. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40885.x · Cited by 620
Rao, S., Lembo, A. J., Shiff, S. J., Lavins, B. J., Currie, M. G., Jia, X. D., Shi, K., MacDougall, J. E., Shao, J. Z., Eng, P., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.255 · Cited by 384
Ford, A. C., & Suares, N. C. (2011) · Gut · doi:10.1136/gut.2010.227132 · Cited by 378
The burden of constipation on quality of life: results of a multinational survey
WALD, A., SCARPIGNATO, C., KAMM, M. A., MUELLER‐LISSNER, S., HELFRICH, I., SCHUIJT, C., BUBECK, J., LIMONI, C., & PETRINI, O. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03376.x · Cited by 376
Two randomized trials of linaclotide for chronic constipation
Lembo, A. J., Schneier, H. A., Shiff, S. J., Kurtz, C. B., MacDougall, J. E., Jia, X. D., Shao, J. Z., Lavins, B. J., Currie, M. G., Fitch, D. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010863 · Cited by 373
Diagnosis and treatment of chronic constipation - a European perspective
Tack, J., Müller-Lissner, S., Stanghellini, V., Boeckxstaens, G., Kamm, M. A., Simren, M., Galmiche, J.-P., & Fried, M. (2011) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2011.01709.x · Cited by 304
Research works printed but not linked: 1
- Sakimura, 1998, Clinical evaluation of YO-106 (magnesium oxide tablets) in the treatment of habitual constipation—A cross over study with magnesium oxide powders, Jpn Pharmacol Ther, 26, 1027
Cited by
Chang, L., Chey, W. D., Imdad, A., Almario, C. V., Bharucha, A. E., Diem, S., Greer, K. B., Hanson, B., Harris, L. A., Ko, C., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.03.214 · Cited by 185
Magnesium Oxide in Constipation
Mori, H., Tack, J. F., & Suzuki, H. (2021) · Nutrients · doi:10.3390/nu13020421 · Cited by 119
Rao, S. S. C., & Brenner, D. M. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001222 · Cited by 97
Idiopathic Slow Transit Constipation: Pathophysiology, Diagnosis, and Management
Vlismas, L. J., Wu, W. K. K., & Ho, V. (2024) · Medicina · doi:10.3390/medicina60010108 · Cited by 68
“Magnesium oxide is an alternative that has been shown to improve the frequency of bowel movements and quality of life when compared with the placebo, but patients should be monitored for hypermagnesaemia, particularly those with renal impairment [18,35,37].”
BackgroundEvidence-Based Clinical Guidelines for Chronic Constipation 2023
Ihara, E., Manabe, N., Ohkubo, H., Ogasawara, N., Ogino, H., Kakimoto, K., Kanazawa, M., Kawahara, H., Kusano, C., Kuribayashi, S., et al. (2024) · Digestion · doi:10.1159/000540912 · Cited by 95
“Saline laxatives: magnesium oxide has been shown to be effective in RCTs [139 – 141].”
Self-citation
Metadata
- Authors
- Morishita, D., Tomita, T., Mori, S., Kimura, T., Oshima, T., Fukui, H., & Miwa, H.
- Affiliations
- Hyogo Medical University (JP)
- Corresponding author
- Miwa, Hiroto
- Venue
- American Journal of Gastroenterology
- Published
- 2020-09-22
- Volume
- 116
- Issue
- 1
- Pages
- 152-161
- ISSN
- 0002-9270 (ISSN-L)
- 1572-0241
- OpenAlex
- W3087944579
- Cited by
- 65
- References
- 39
- Citations by year
- 2026: 12 · 2025: 5 · 2024: 13 · 2023: 17 · 2022: 12 · 2021: 5 · 2020: 1
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
- Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
- Keywords
- chronic idiopathic constipation, Senna, magnesium oxide, stimulant laxatives, osmotic laxatives, spontaneous bowel movements, constipation quality of life
- MeSH terms
- Sennosides, Adult, Aged, Chronic Disease, Constipation, Double-Blind Method, Female, Humans, Magnesium Oxide, Male, Middle Aged, Quality of Life, Treatment Outcome, Laxatives, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Senna Versus Magnesium Oxide for the Treatment of Chronic Constipation: A Randomized, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.14309/ajg.0000000000000942
- The paper
- Morishita, D., Tomita, T., Mori, S., Kimura, T., Oshima, T., Fukui, H., & Miwa, H. (2021). Senna Versus Magnesium Oxide for the Treatment of Chronic Constipation: A Randomized, Placebo-Controlled Trial. American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000000942
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.